Skip to main content

Antiangiogenic Agents in Cancer Therapy

  • Book
  • © 2008

Overview

  • Current perspectives on state-of-the-art therapies
  • Contains chapters specific to angiogenesis and antiangiogenic treatment of many malignant diseases

Part of the book series: Cancer Drug Discovery and Development (CDD&D)

This is a preview of subscription content, log in via an institution to check access.

Access this book

eBook USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (31 chapters)

  1. Basic Biology of Angiogenesis

  2. Translational Research in Tumor Angiogenesis

Keywords

About this book

Antiangiogenesis remains a dynamic and evolving field in oncology. New therapeutic targets continue to emerge followed by the rapid development of new therapeutic agents to be investigated in clinical trials. Optimizing the therapeutic potential of antiangiogenic agents in combination with the other therapies in the armamentarium to fight cancer will be an on-going challenge. Antiangiogenic Agents in Cancer Therapy, Second Edition provides a current, up-dated perspective on the state of the art of angiogenesis and therapy with a compendium of scientific findings and approaches to the study of angiogenesis in cancer.  Leaders in the field present chapters on such topics as the environmental influences and the genetic and physiologic abnormalities that mediate angiogenesis and its role in the progression of malignant disease, working models of tumor angiogenesis, and the role of angiogenesis inhibition in the therapy of malignant disease in humans. 

Comprehensive and cutting-edge, Antiangiogenic Agents in Cancer Therapy, Second Edition is an ideal, valuable guide to the most recent advances in the field, and a collection that will be useful for many years to come.

Reviews

From the reviews of the second edition:

"This is a second edition of a well-accepted text on angiogenesis and antiangiogenic agents, particularly on their use in cancer therapy. In addition to the editors, a large number of outstanding investigators have contributed to this book. … This edition is highly recommended to all of those involved in research or the clinical practice of oncology." (Julian L. Ambrus and Clara M. Ambrus, The Journal of Medicine, March, 2008)

Editors and Affiliations

  • Genzyme Corporation, Framingham

    Beverly A. Teicher

  • M. D. Anderson Cancer Center, The University of Texas, Houston

    Lee M. Ellis

Bibliographic Information

  • Book Title: Antiangiogenic Agents in Cancer Therapy

  • Editors: Beverly A. Teicher, Lee M. Ellis

  • Series Title: Cancer Drug Discovery and Development

  • DOI: https://doi.org/10.1007/978-1-59745-184-0

  • Publisher: Humana Totowa, NJ

  • eBook Packages: Medicine, Medicine (R0)

  • Copyright Information: Humana Press 2008

  • Hardcover ISBN: 978-1-58829-870-6Published: 12 December 2007

  • Softcover ISBN: 978-1-4939-5628-9Published: 23 August 2016

  • eBook ISBN: 978-1-59745-184-0Published: 08 January 2008

  • Series ISSN: 2196-9906

  • Series E-ISSN: 2196-9914

  • Edition Number: 2

  • Number of Pages: XVIII, 559

  • Topics: Cancer Research, Oncology, Surgical Oncology, Pharmacology/Toxicology

Publish with us